Correction to: J Transl Med (2020) 18:238 10.1186/s12967-020-02413-w
After publication of the original article [1], the authors identified errors in Tables 1 and 2. The correct tables are given below.
Table 1.
Baseline characteristic of participants according to different BP patterns diagnosed by criterion A
| Total (N = 1714) | NT (N = 672) | WCH (N = 81) | MH (N + (N = 529) | SH (N = 432) | P | |
|---|---|---|---|---|---|---|
| Age (years) | 48.9 ± 13.8 | 46.7 ± 14.4 | 53.1 ± 14.4a | 49.9 ± 12.8ab | 50.0 ± 13.3ab | < 0.001 |
| Male, n (%) | 974 (56.8%) | 321 (47.8%) | 38 (46.9%) | 318 (60.1%)ab | 297 (68.8%)abc | < 0.001 |
| BMI (kg/m2) | 24.6 ± 3.9 | 23.9 ± 3.6 | 25.0 ± 4.0a | 24.8 ± 3.8a | 25.6 ± 4.1ac | < 0.001 |
| Smokers, n (%) | 623 (36.8%) | 188 (28.2%) | 24 (30.8%) | 213 (40.7%)a | 198 (46.7%)abc | < 0.001 |
| DM, n (%) | 366 (24.7%) | 94 (16.5%) | 18 (26.1%)a | 123 (26.9%)a | 131 (34.2%)abc | < 0.001 |
| CVD history, n (%) | 155 (9.0%) | 41 (6.1%) | 12 (14.8%) | 55 (10.4%) | 47 (10.9%) | 0.004 |
| Anti-hypertension, n (%) treatment | 1245 (76.7%) | 380 (61.8%) | 66 (85.7%)a | 422 (81.8%)a | 377 (90.8%)ac | < 0.001 |
| Causes of CKD* | < 0.001 | |||||
| DKD | 212 (12.4%) | 35 (5.2%) | 11 (13.6%)a | 73 (13.8%)a | 93 (21.5%)abc | |
| GN | 1048 (61.1%) | 489 (72.8%) | 40 (49.4%)a | 313 (59.2%)a | 206 (47.7%)ac | |
| Others | 442 (25.8%) | 144 (21.4%) | 29 (35.8%)a | 140 (26.5%) | 129 (29.9%)a | |
| ALB (g/L) | 38.3 ± 7.4 | 38.7 ± 7.2 | 39.4 ± 5.2 | 38.2 ± 7.6 | 37.7 ± 7.9a | 0.1 |
| FBG (mmol/L) | 4.9 (4.4, 5.6) | 4.8 (4.3, 5.4) | 5.0 (4.5, 5.5) | 4.9 (4.4, 5.7)a | 5.0 (4.5, 5.9)a | 0.004 |
| HGB (g/L) | 126.5 ± 22.4 | 127.7 ± 19.55 | 121.9 ± 22.2a | 126.3 ± 24.2 | 125.7 ± 24.5 | 0.1 |
| TG (mmol/L) | 1.8 (1.2, 2.5) | 1.7 (1.2, 2.4) | 1.8 (1.3, 2.4) | 1.9 (1.3, 2.6)a | 1.9 (1.3, 2.6)a | 0.004 |
| TC (mmol/L) | 4.7 (3.9, 5.7) | 4.7 (3.9, 5.7) | 4.6 (3.8, 5.5) | 4.7 (3.9, 5.6) | 4.7 (3.9, 5.7) | 0.8 |
| HDLC (mmol/L) | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.4) | 1.0 (0.9, 1.3) | 1.0 (0.9, 1.3)a | 1.1 (0.9, 1.2)a | 0.001 |
| LDLC (mmol/L) | 2.6 (2.1, 3.2) | 2.6 (2.1, 3.2) | 2.6 (2.1, 3.2) | 2.5 (2.1, 3.2) | 2.7 (2.2, 3.3) | 0.5 |
| Cr (μmol/L) | 98 (141, 198) | 116.0 (80.0, 164.2) | 153.0 (106.7, 218.4)a | 151.0 (108.0, 204.5)a | 167.0 (122.0, 243.2)ac | < 0.001 |
| eGFR (mL/min/1.73 m2) | 52.2 ± 30.1 | 62.9 ± 32.7 | 43.3 ± 24.3a | 48.2 ± 28.2a | 42.2 ± 23.3ac | < 0.001 |
| 24 h-Upro (g/L) | 1.0 (0.4, 2.4) | 0.7 (0.3, 1.5) | 1.0 (0.4, 2.9)a | 1.1 (0.4, 2.5)a | 1.8 (0.8, 3.5)abc | < 0.001 |
| CKD stages, n (%) | < 0.001 | |||||
| 1 | 256 (14.9%) | 174 (25.9%) | 5 (6.2%)a | 55 (10.4%)a | 22 (5.1%)ac | |
| 2 | 305 (17.8%) | 144 (21.4%) | 11 (13.6%) | 90 (17.0%) | 60 (13.9%)a | |
| 3 | 676 (39.5%) | 228 (33.9%) | 36 (44.4%) | 220 (41.6%)a | 192 (44.5%)a | |
| 4 | 477 (27.8%) | 126 (18.8%) | 29 (35.8%)a | 164 (31.0%)a | 158 (36.6%)a |
* The diagnosis was made mainly basing on medical history and clinical features, with only 578 patients having renal biopsy confirmation. Among them, 513 patients were diagnosed as GN. IgAN constituted the majority of GN group (54.2%), following by mesangial proliferative glomerulonephritis (32.2%) and membranous nephropathy (10.5%). Others group included hypertensive nephropathy, tubulointerstitial nephritis, and cause unknown etc
aP < 0.05 comparison with NT
bP < 0.05 comparison with WCH
cP < 0.05 comparison with MH
Table 2.
Clinical and ambulatory BP parameters of patients
| Total | NT | WCH | MH | SH | P | |
|---|---|---|---|---|---|---|
| Criterion A | ||||||
| Clinic SBP (mmHg) | 129.5 ± 17.3 | 118.6 ± 11.1 | 143.1 ± 13.4a | 124.9 ± 9.4ab | 149.4 ± 14.6abc | < 0.001 |
| Clinic DBP(mmHg) | 80.6 ± 10.4 | 74.8 ± 7.4 | 87.9 ± 9.1a | 78.6 ± 6.5ab | 90.8 ± 10.5abc | < 0.001 |
| 24 h-SBP (mmHg) | 128.3 ± 17.0 | 114.5 ± 8.3 | 118.3 ± 7.3a | 134.8 ± 13.0ab | 143.6 ± 15.0abc | < 0.001 |
| 24 h-DBP (mmHg) | 79.3 ± 10.8 | 70.9 ± 6.0 | 70.6 ± 5.9 | 84.5 ± 8.2ab | 87.4 ± 10.0abc | < 0.001 |
| D-SBP (mmHg) | 131.1 ± 17.0 | 116.7 ± 8.9 | 120.4 ± 7.5a | 136.4 ± 13.1ab | 145.1 ± 15.3abc | < 0.001 |
| D-DBP (mmHg) | 80.7 ± 11.0 | 72.6 ± 6.3 | 72.3 ± 6.3 | 85.8 ± 8.5ab | 88.6 ± 10.5abc | < 0.001 |
| N-SBP (mmHg) | 123.6 ± 18.7 | 109.6 ± 10.0 | 113.9 ± 10.5a | 130.4 ± 15.1ab | 138.9 ± 17.7abc | < 0.001 |
| N-DBP (mmHg) | 75.4 ± 12.5 | 66.7 ± 7.5 | 66.6 ± 9.3 | 80.6 ± 11.1ab | 84.1 ± 11.1abc | < 0.001 |
| Criterion B | ||||||
| Clinic SBP (mmHg) | 129.5 ± 17.3 | 113.4 ± 9.7 | 131.6 ± 12.0a | 117.4 ± 8.9ab | 139.1 ± 15.9abc | < 0.001 |
| Clinic DBP (mmHg) | 80.6 ± 10.4 | 70.7 ± 6.2 | 83.4 ± 7.0a | 73.0 ± 5.5ab | 86.2 ± 9.5abc | < 0.001 |
| 24 h-SBP (mmHg) | 128.3 ± 17.0 | 112.0 ± 8.3 | 116.7 ± 8.0a | 131.5 ± 12.3ab | 138.6 ± 15.2abc | < 0.001 |
| 24 h-DBP (mmHg) | 79.3 ± 10.8 | 69.0 ± 5.9 | 71.7 ± 5.8a | 81.7 ± 8.1ab | 85.7 ± 9.5abc | < 0.001 |
| D-SBP (mmHg) | 131.1 ± 17.0 | 113.8 ± 8.3 | 117.7 ± 7.3a | 133.8 ± 12.2ab | 140.4 ± 15.1abc | < 0.001 |
| D-DBP (mmHg) | 80.7 ± 11.0 | 70.5 ± 5. 9 | 72.6 ± 5.4a | 83.7 ± 8.0ab | 87.1 ± 9.6abc | < 0.001 |
| N-SBP (mmHg) | 123.6 ± 18.7 | 107.5 ± 10.8 | 113.5 ± 10.8a | 125.4 ± 14.4ab | 133.6 ± 17.8abc | < 0.001 |
| N-DBP (mmHg) | 75.4 ± 12.5 | 64.9 ± 7.5 | 69.0 ± 7.9a | 76.9 ± 9.7ab | 81.9 ± 10.7abc | < 0.001 |
24 h-SBP 24-hour average ambulatory systolic blood pressure, 24 h-DBP 24-hour average ambulatory diastolic blood pressure, D-SBP daytime systolic blood pressure, D-DBP daytime diastolic blood pressure, N-SBP nighttime systolic blood pressure, N-DBP nighttime diastolic blood pressure
The original article has been corrected.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Yu Wang, Email: ddwangyu@sina.com.
the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE):
Ming-Hui Zhao, Luxia Zhang, Xiaoqin Wang, Jun Yuan, Qiaoling Zhou, Qiongjing Yuan, Menghua Chen, Xiaoling Zhou, Shuxia Fu, Shaomei Li, Yan Zha, Rongsai Huang, Zhangsuo Liu, JunJun Zhang, Li Wang, Lei Pu, Jian Liu, Suhua Li, Zuying Xiong, Wei Liang, Jinghong Zhao, Jiao Mu, Xiyan Lian, Yunjuan Liao, Hua Gan, Liping Liao, Rong Wang, Zhimei Lv, Yunhua Liao, Ling Pan, Xiaoping Yang, Zhifeng Lin, Zongwu Tong, Yun Zhu, Qiang He, Fuquan Wu, Rong Li, Kai Rong, Caili Wang, Yanhui Zhang, Yue Wang, Wen Tang, Hua Wu, Ban Zhao, Rongshan Li, Lihua Wang, Detian Li, Feng Du, Yonggui Wu, Wei Zhang, Shan Lin, Pengcheng Xu, Hongli Lin, Zhao Hu, Fei Pei, Haisong Zhang, Yan Gao, Luying Sun, Xia Li, Wenke Wang, Fengling Lv, Deguang Wang, Xuerong Wang, Dongmei Xu, Lijun Tang, Yingchun Ma, Tingting Wang, Ping Fu, Tingli Wang, Changying Xing, Chengning Zhang, Xudong Xu, Haidong He, Xiaohui Liao, Shuqin Xie, Guicai Hu, and Lan Huang
Reference
- 1.Wang Q, Wang Y, Wang J, Zhang L, Zhao M, the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE) White-coat hypertension and incident end-stage renal disease in patients with non-dialysis chronic kidney disease: results from the C-STRIDE Study. J Transl Med. 2020;18:238. doi: 10.1186/s12967-020-02413-w. [DOI] [PMC free article] [PubMed] [Google Scholar]